01 6Mircera
02 1NeoRecormon
03 4NeoRecormon/Epogin
04 2Neorecormon/Epogin
Methoxy Polyethylene Glycol-Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 609
2018 Revenue in Millions : 548
Growth (%) : 11
Methoxy Polyethylene Glycol-Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 270
2018 Revenue in Millions : 297
Growth (%) : -9
Methoxy Polyethylene Glycol-Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 266
2019 Revenue in Millions : 292
Growth (%) : -9
Methoxy Polyethylene Glycol-Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 524
2019 Revenue in Millions : 658
Growth (%) : -20
Methoxy Polyethylene Glycol and Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 468
2020 Revenue in Millions : 498
Growth (%) : -7
Methoxy Polyethylene Glycol-Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 446
2021 Revenue in Millions : 468
Growth (%) : -5
Methoxy Polyethylene Glycol-Epoetin Beta
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 494
2022 Revenue in Millions : 446
Growth (%) : 4
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2014 Revenue in Millions : -11.50%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2015 Revenue in Millions : 465
2014 Revenue in Millions : 370
Growth (%) : -20%
Main Therapeutic Indication : Blood Disorders
Currency : USD
2016 Revenue in Millions : 325
2015 Revenue in Millions : 362
Growth (%) : -10
